Abstract: Objective The purpose of this study was to investigate efficacy and safety of solimbuvir combined with danorevir and ribavirin in the treatment of naïve patients with hepatitis C viral genotype 3 infection. Methods 104 patients with chronic hepatitis C (CHC) with genotype 3 infection were enrolled in our hospital between January 2019 and December 2023, and were randomly assigned to receive sorfosbuvir plus danorevir and ribavirin combination treatment (observation, n=52) for 12 weeks, or to receive pegylated interferon α-2a and ribavirin antiviral treatment for 24 weeks. All patients were followed-up for 24 weeks after discontinuation of antiviral therapy. Serum HCV RNA loads were assayed routinely and liver stiffness measurement (LSM) was detected by Fibroscan. Results The rapid virological response (RVR), early virological response (EVR), end of treatment virological response (ETVR) and sustained virological response rates (SVR) in the observation group were 67.3%, 88.5%,100.0% and 98.1%, all significantly higher than 15.4%, 19.2%,69.2% and 61.5% (P<0.05) in the control; by end of antiviral treatment, serum ALT, AST and LSM in the observation group were (36.2±8.5)U/L, (37.2±8.2)U/L and (7.1±1.3)kPa, all much lower than [(57.3±7.2)U/L, (49.6±6.2)U/L and (8.5±1.2)kPa, respectively, P<0.05] in the control group; during antiviral treatment, incidences of adverse effects, such as fever, granulocytopenia, thrombocytopenia and anorexia in the control group were 98.1%, 88.5%, 48.1% and 48.1%, all much higher than 0.0%, 20.3%, 13.3% and 9.6% (P<0.05) in the observation group. Conclusions The combination of soropovir plus danorevir and ribavirin in the treatment of naivepatients with CHC and hepatitis C viral genotype 3 infection could obtain a satisfactory clinical short-term efficacy, which is relatively safe and warrants further observation.

Key words: Hepatitis C, Hepatitis C viral genotype 3, Daunorivir, Solimbuvir, Ribavirin, Therapy